AgomAb Therapeutics N.V. announced today the closing of a $74 Million Series B financing round, led by Redmile Group with participation from Cormorant Capital and existing investors Pontifax, Andera Partners, Omnes Capital, Advent France Biotechnology and V-Bio Ventures.